Doctor of Podiatric Medicine Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Charles Blaine

Podiatrist Glendale, CA Doctor of Podiatric Medicine

NPI 1811088578 CMS profile 414826

1510 S Central Ave, Suite 120, Glendale, CA 91204

Open in the dashboard

General payments

$2,872

40 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Charles Blaine of Glendale, CA is reported in the CMS Open Payments database as having received $2,872 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $122 1
2022 General $21 1
2021 General $134 6
2020 General $216 7
2019 General $2,380 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Blaine
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Charles Blaine were reported at $0. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Charles Blaine Podiatrist median Middle half National median
2019 $2,380 $196 $72–$601 $163
2020 $216 $118 $38–$335 $114
2021 $134 $169 $57–$573 $132
2022 $21 $220 $74–$782 $149
2023 $122 $208 $71–$635 $160
2024 $0 $237 $87–$681 $164
2025 $0 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Linvatec Corporation $1,007 5 payments
  2. Paragon 28, Inc. $886 4 payments
  3. Smith+Nephew, Inc. $272 9 payments
  4. Horizon Therapeutics plc $143 2 payments
  5. Cardiovascular Systems Inc. $136 3 payments
  6. Organogenesis Inc. $123 3 payments
  7. Paratek Pharmaceuticals, Inc. $93 4 payments
  8. Tactile Systems Technology Inc $66 4 payments
  9. Zimmer Biomet Holdings, Inc. $33 1 payment
  10. Wright Medical Technology, Inc. $28 1 payment
  11. Other $84 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,450 28 payments
  2. Travel and Lodging $1,330 5 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $86 1 payment
  4. Education $6 6 payments
Products named General payments · program years 2019–2023
  1. LINVATEC EXTREMITIES $690 3 payments
  2. LINVATEC BURS AND BLADES $317 2 payments
  3. KRYSTEXXA $143 2 payments
  4. GRAFIX Other Advanced Wound Management $122 1 payment
  5. Stravix Other Advanced Wound Management $122 1 payment
  6. GrafixPL $122 1 payment
  7. OASIS $122 1 payment
  8. GRAFIX Other Advanced Wound Management $122 1 payment
  9. STRAVIX Extremities & Limb Restoration $122 1 payment
  10. Peripheral Orbital Atherectomy System $114 2 payments
  11. Other $762 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record